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Summary
 
Recent studies using interleukin (IL)-4–deficient animals have highlighted the existence of IL-
4–independent immunoglobulin (Ig)E induction. We have established transgenic mice express-
ing IL-13 from a transgene comprising a genomic fragment containing the IL-13 gene and the
human CD2 locus control region. The transgenes were expressed in lymphoid tissues and in-
duced by T cell activators, suggesting regulation by elements of the IL-13 promoter. IL-13
transgenic lines expressed 10–100-fold higher levels of serum IgE than their littermate controls,
but had normal levels of other serum Ig isotypes. Elevated IgE levels were also detected in sera
from IL-4–deficient mice carrying IL-13 transgenes, indicating that IL-4 is not required for IL-
13–induced IgE expression in the mouse. Expression of IL-13 also perturbed the development
of thymocytes. Although thymocyte development was normal up to 4 wk of age, thymocyte
number decreased dramatically thereafter, reaching 10% of normal by 10 wk, and despite nor-
mal size and appearance, histological examination demonstrated that transgenic thymi con-
tained only small foci of thymocytes. The reduction in thymocyte number was due mainly to a
depletion of CD4
 
1
 
CD8
 
1
 
 thymocytes, and did not affect significantly the composition of pe-
ripheral T cell populations. These data indicate that expression of IL-13 transgenes in vivo can
regulate IgE production in the mouse, and that IL-13 may also influence thymocyte develop-
ment.
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C
 
ytokines, it is clear, can modulate B cell function by
differentially stimulating specific Ig isotype produc-
tion. Consequently, if antigenic challenge elicits a Th1 cell
response characterized by high levels of IFN-
 
g
 
, there is an
associated increase in the level of IgG2a production. Simi-
larly, immune responses developing a Th2 cell phenotype
exhibit high levels of IL-4 and develop elevated serum IgE
and IgG1 (for a review, see reference 1). The intrinsic role
played by IgE in the development of asthma and allergic
responses highlights the importance of understanding the
mechanisms controlling its production. IL-4 was believed
to be solely responsible for the expression of IgE in the
mouse (2–6); however, recent studies using IL-4–deficient
mice have clearly shown that IgE can be generated in the
complete absence of IL-4 (7, 8), indicating that other
mechanisms can mediate IgE production in mice. The dis-
covery of IL-13 and the demonstration that this cytokine
could also induce IgE production by human B cells estab-
lished that a further layer of complexity existed in the regu-
lation of IgE (9–11). IL-13 is a cytokine produced predom-
inantly by Th2 and mast cells, and it shares structural and
functional similarities with IL-4 (12, 13). Significantly, ad-
dition of IL-13 to in vitro assays has so far failed to induce
IgE production by mouse B cells, leading to reports that
IL-13 cannot regulate IgE in the mouse (13).
In this paper, we describe the production of IL-13 trans-
genic mouse lines and present data confirming a role for
IL-13 in the development of an IL-4–independent IgE re-
sponse.
 
Materials and Methods
 
Generation of IL-13 Transgenic Mice.
 
A 6.0-kb BamHI-digested
genomic DNA fragment containing the complete mouse IL-13
gene (14) was cloned into a BamHI site upstream of the human
CD2 locus control region (LCR; reference 15) in the vector
GSE1515 (supplied by Dimitris Kioussis, National Institute for
Medical Research, London, UK). The IL-13 and CD2 LCR
gene fusion was isolated as an 11.5-kb NotI fragment and injected
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into eggs. Transgenic mice (strain CBA 
 
3
 
 C57BL/6) were gen-
erated using standard protocols (16). Transgenic mice were iden-
tified using Southern blot analysis of genomic DNA hybridized
with the CD2 LCR or the mouse IL-13 cDNA (12). In the ex-
periments presented, transgenic lines IL13Tg431 and IL13Tg478 had
been backcrossed four times onto strain C57BL/6. IL13Tg431
mice were crossed with IL-4–deficient mice (A.N.J. McKenzie,
unpublished data) or IL-4T (5) to derive IL-13Tg
 
1
 
/IL-4
 
2
 
/
 
2
 
 off-
spring. In all experiments presented, transgenic mice were com-
pared with wild-type littermate controls. Mice were maintained
in a specific pathogen–free animal facility.
 
RNA Analysis.
 
Total RNA was isolated from muscle, kidney,
spleen, thymus, bone marrow, heart, and liver using RNAzolB (Bio-
tecx, Biogenesis Laboratories, Poole, UK). Reverse transcription
(RT)-PCR primers for IL-13 were 5
 
9
 
-GGGTGACTGCAG-
TCCTGGCT-3
 
9
 
 and 5
 
9
 
-GCTGGAGACCGTAGTGGG-3
 
9
 
. Hy-
poxanthine phosphoribosyltransferase (HPRT) primers and con-
ditions were as described previously (17).
 
Cytokine and Ig ELISAs.
 
Serum Igs were assayed using sand-
wich ELISA. 96-well plates were coated with anti-Ig isotype cap-
ture mAbs, and bound Ig of diluted serum samples was detected
using biotinylated anti-Ig isotype detection mAbs (PharMingen,
San Diego, CA). Concentrations were calculated using purified
Igs as standards (PharMingen). The IL-13 ELISA was purchased
from R&D Systems (Abingdon, UK).
 
Analysis of IL-13 Production.
 
LN cells were resuspended at 2 
 
3
 
10
 
6
 
 cells/ml in RPMI 1640 glutamax medium (GIBCO BRL,
Paisley, UK), supplemented with 0.05 mM 2-ME, 100 U/ml
penicillin, 100 
 
m
 
g/ml streptomycin, and 10% FCS, or this me-
dium supplemented with Con A (2 
 
m
 
g/ml). After incubation, su-
pernatants were harvested and assayed for the presence of IL-13
using ELISA.
 
Immunofluorescent Flow Cytometry.
 
Single cell suspensions were
prepared from thymus, spleen, and LN. Cells were stained with
FITC–anti-CD4 Ab (clone H129.19) and PE–anti-CD8 Ab
(clone 53-6.7) and analyzed by flow cytometry (FACSCalibur
 
Ò
 
;
Becton Dickinson, San Jose, CA). LN cells were stained with
FITC–anti-CD45R/B220 (clone RA3-6B2) and PE–anti-CD23
Ab (clone B3B4). For three-color staining, thymocytes were
stained with FITC–anti-CD4, FITC–anti-CD8, FITC–anti-
CD3
 
e
 
 (clone 2C11), PE–anti-CD44 (clone IM7), and biotin-
conjugated anti-CD25 (clone H129.19, detected with streptavi-
din–Cy-Chrome). All Abs were purchased from PharMingen.
 
Results and Discussion
 
Inducible Tissue-specific IL-13 Expression in IL-13 Transgenic
Mouse Lines.
 
Since IL-13 is primarily produced by T cells,
we chose to facilitate transgene expression in the T lympho-
cyte compartment. To achieve this, we cloned the native
mouse IL-13 gene containing 
 
z
 
3 kb of upstream sequence
into the 5
 
9
 
 region of the human CD2 LCR (Fig. 1 
 
A
 
). Us-
ing egg injection, several transgenic founders were gener-
ated that varied in the number of integrated copies of the
IL-13 gene. Three founders were used to establish inde-
pendent transgenic lines denoted IL13Tg431 (
 
z
 
6 copies of
the transgene), IL13Tg478 (
 
z
 
10 copies), and IL13Tg520
(
 
z
 
15 copies), which were analyzed in more detail. Al-
though the data from IL13Tg520 were consistent with
those obtained with the other two transgenic lines, they are
not presented here because we have determined that the
transgenes in this line are on the Y chromosome, thus pre-
venting the use of sex-matched littermate controls.
RT-PCR analysis on cDNA from several tissues clearly
demonstrated that expression of IL-13 mRNA was limited
to lymphoid tissues, and that this expression was more
prevalent in the IL-13 transgenic animals (Fig. 1 
 
B
 
). In ad-
dition to the tissue specificity of IL-13 transgene expres-
sion, the IL-13 transgene also retained a significant level of
activation control. When wild-type and IL-13 transgenic
LN cells were cultured in the absence of stimulation, the
concentrations of IL-13 protein were below levels of de-
tection (
 
,
 
5 pg/ml). However, upon stimulation with the
polyclonal activator Con A, IL-13 expression is induced,
with the levels of IL-13 protein produced correlating with
the number of copies of the IL-13 genes present, such that
IL13Tg478 
 
. 
 
IL13Tg431 
 
. 
 
wild-type mice (Fig. 1 
 
C
 
).
These data demonstrate that the genomic region containing
the IL-13 gene retains a capacity for inducible expression,
and that IL-13 production is transgene copy number de-
pendent and tissue specific.
 
Serum Ig Analysis.
 
Total serum IgE from naive animals
was highly elevated in both of the IL-13 transgenic lines.
Indeed, IgE levels were 10-fold greater than normal in
IL13Tg431 mice and up to 100-fold higher than normal in
the IL13Tg478 animals (Fig. 2 
 
A
 
), indicating that IgE levels
increased with the number of integrated copies of the IL-13
gene. In contrast, total serum Ig titers of IgG1, IgG2a,
IgG2b, IgA, and IgM were similar in the wild-type,
IL13Tg431 (Fig. 2 
 
A
 
), and IL-13Tg478 mice (data not
shown). The elevated levels of IgE in the IL-13 transgenics
were readily detected in mice at 3, 6, and 
 
.
 
10 wk of age
(data not shown). Thus, IL-13 expression induces a highly
specific upregulation of IgE.
Figure 1. Construction and expression pattern of IL-13
transgene. (A) Map of the mouse IL-13/human CD2
transgene construct. Black boxes, IL-13 exons. Shaded box,
Human CD2 (hCD2) LCR. N, NotI; B, BamHI; Bg,
BglII. (B) Total RNA from tissues of IL13Tg431 mice (Tg)
and wild-type littermates (wt) analyzed by RT-PCR using
IL-13–specific and HPRT primers. (C) IL-13 secretion by
activated mesenteric LN cells derived from wild-type mice
and IL-13 transgenic littermates. Mesenteric LN cells were
cultured in the presence of media, or media containing
Con A for the times indicated, and culture supernatants
were assayed using IL-13 ELISA. Data were obtained from
four wild-type or four transgenic mice in each group. 
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To date, IL-13 has not been demonstrated to regulate
IgE switching by mouse B cells in vitro. However, in vivo
it is unclear whether IL-13 may mediate its effect directly
on B cells or indirectly by modulating other cell types that
may influence IgE expression. Although we did not detect
a significant increase in total B cell numbers (data not
shown), it is possible that IL-13 may be directing the spe-
cific outgrowth of IgE-expressing cells in the IL-13 trans-
genics. Alternatively, and in common with its role on hu-
man B cells (11), IL-13 may be acting as an alternative
switch factor for IgE transcription. Although IL-4 is a po-
tent IgE differentiation signal for mouse B cells both in
vitro (2–6) and in transgenic mice (18, 19), it is also appar-
ent that other factors are able to regulate IgE switching in
the mouse. Recent studies have demonstrated that al-
though IL-4–deficient mice generally exhibit undetectable
levels of IgE, these animals can still produce IgE after cer-
tain antigenic challenge or infection (7, 8). We were un-
able to detect any changes in the transcription of the IL-4
gene or increased expression of the IL-4 protein from LN
cells or splenocytes prepared from the IL-13 transgenic ani-
mals (data not shown). To investigate whether IL-13 could
still induce IgE expression in the absence of IL-4, we
crossed IL-13 transgenics with IL-4–deficient mice. In
contrast to naive IL-4
 
2
 
/
 
2
 
 animals, in which IgE levels were
below the levels of detection, all naive IL-4
 
2
 
/
 
2
 
IL13Tg
 
1
 
animals expressed high levels of IgE (Fig. 2 
 
B
 
). These data
demonstrate that IL-13 induces IgE expression in an IL-
4–independent manner. IL-13 transgene expression did not
reverse the IgG1 deficiency reported in the IL-4–deficient
mice (Fig. 2 
 
B
 
), indicating that IL-13 does not appear to
regulate IgG1 production, and correlating with unchanged
levels of IgG1 detected in IL-13–deficient mice (20). It is
noteworthy that we have detected reduced levels of IgE in
IL-13–deficient mice (20), indicating that both upregula-
tion and downregulation of IL-13 can modulate IgE levels
in mice. These findings lead us to conclude that IL-13 can
modulate IgE levels in mice as well as in humans, but for
unknown reasons, this effect cannot be detected using cur-
rent in vitro mouse B cell differentiation assays (13). In-
deed, the contrast between our in vivo results and previous
in vitro findings may indicate that IL-13 mediates its role in
IgE induction by the regulation of additional cell types.
Coincident with the increase in IgE production, we also
observed an elevation in the expression levels of CD23 on
B220
 
1
 
 cells from mesenteric LNs (Fig. 2 
 
C
 
) and spleen
(data not shown) of IL-13 transgenic mice. These data con-
trast with a report in which IL-13 failed to modulate CD23
on mouse B cells in vitro (13), but are in agreement with
reports that IL-13 can upregulate CD23 on human B cells
(11). We have also found that CD23 expression is lower on
B cells from IL-13–deficient mice (our unpublished obser-
vations). Therefore, our data indicate that in vivo IL-13
can also regulate other facets of the IgE response by B cells.
 
Perturbation of Thymocyte Development.
 
Thymocyte de-
velopment in IL-13 transgenic mice was severely affected
as the mice aged. Thymocyte populations from 1- and
4-wk-old transgenic animals developed normally (data not
shown); however, by 6 wk of age, thymocyte numbers in
the thymi of IL-13 transgenic animals began to fall to 
 
z
 
50–
75% of normal. By 10 wk of age, the number of thy-
mocytes was reduced to 
 
z
 
10% of normal thymocyte num-
ber, although thymus size appeared normal. Analysis using
the T cell markers CD4 and CD8 indicated that the most
significant thymocyte loss was from the CD4
 
1
 
CD8
 
1
 
 subset
in the thymi of IL-13 transgenic mice, although CD4
 
1
 
CD8
 
2
 
and CD4
 
2
 
CD8
 
1
 
 cell numbers were also reduced (Fig. 3 
 
A
 
).
The numbers of CD4
 
2
 
CD8
 
2
 
 cells in the thymus remained
equivalent in the IL-13 transgenic mice and their wild-type
littermates. However, when CD4
 
2
 
CD8
 
2
 
CD3
 
2
 
 cells were
analyzed for their expression of the T cell developmental
markers CD44 and CD25, the wild-type cells comprised a sig-
nificantly greater proportion of more mature CD44
 
1
 
CD25
 
1
 
cells compared with the IL-13 transgenics, which displayed
far more cells in the immature CD44
 
1
 
CD25
 
2
 
 population
(Fig. 3 
 
B
 
). Histologic sectioning of 10-wk-old thymi from
IL-13 transgenics and their wild-type littermates revealed a
severe breakdown in normal thymus architecture in the IL-13
transgenic animals. Whereas the littermate controls exhib-
ited normal thymic structure consisting of cortex and me-
Figure 2. B cell responses to IL-13
transgene expression. (A) Total serum Ig
isotype production by wild-type mice
and IL-13 transgenic littermates. Repre-
sented data were obtained from six
wild-type, six IL13Tg431, and four IL-
13Tg478 mice. (B) Total serum Ig
isotype production by wild-type,
IL13Tg431, IL-42/2, and IL-42/2IL13Tg1 littermates (five animals per group). (C) Cytofluorometric analysis of CD23 expression on B2201 LN cells.
Mesenteric LN cells from IL-13 transgenic mice and nontransgenic littermates were stained for CD23 expression and gated on B2201 cells. 
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dulla (Fig. 4, 
 
A
 
 and 
 
C
 
), thymi from IL-13 transgenic mice
contained diffuse foci of thymocyte development sur-
rounded by substantial areas of epithelial structure devoid
of thymocytes (Fig. 4, 
 
B
 
 and 
 
D
 
).
Unlike the distorted thymocyte populations observed in
the thymus, there was only a small decrease in CD4
 
1
 
CD8
 
2
 
T cells observed in the peripheral mesenteric LNs of the
IL-13 transgenics compared with their wild-type litter-
mates (Fig. 3 
 
A
 
) and no discernible differences in the CD4/
CD8 numbers or ratios in the spleen (data not shown).
Furthermore, we failed to find any differences in the ex-
pression of a number of other cell surface markers (i.e.,
NK1.1, CD11b, CD117, CD54, or Ly-6G) in spleen, bone
marrow, or thymus (data not shown), and we were unable
to demonstrate any differences in the growth responses of
T or B cells from transgenic mice or wild-type littermates
in response to a range of mitogens (data not shown).
Therefore, although it is unclear how IL-13 mediates the
late onset of thymic depopulation, it is apparent that the
number of mature peripheral T cells is not affected signifi-
cantly, and that macrophage and granulocyte numbers are
unchanged (data not shown).
The apparently normal thymocyte profiles generated
from the IL-13 transgenic animals up to 4 wk of age dem-
onstrate that normal thymocyte development occurs un-
hindered during the early development of the thymus;
however, as evidenced by the severe depletion of thy-
mocytes from 6 through to 10 wk, IL-13 is able to affect
the typical differentiation of immature thymocytes through
the CD4
 
1
 
CD8
 
1
 
 stage. Furthermore, we have found that
inclusion of IL-13 into in vitro fetal thymic organ cultures
also results in an inhibition of thymocyte development
(data not shown). However, it remains to be determined
whether IL-13 acts directly on the T cell populations or if
it mediates its effects by regulating other cell types such as
thymic epithelial cells.
Several other transgenic mouse lines expressing a range of
factors, including soluble cytokines (21–23), transcription fac-
tors (24), or inflammatory molecules (25), have been reported
to develop thymus phenotypes similar to that we have ob-
served in the IL-13 transgenics. Hormones such as estrogen
can also produce a profound reduction in the numbers of dou-
ble positive thymocytes (23), as can the administration of
glucocorticosteroids (26). Although the final outcome on
Figure 4. Histologic sections
from thymi of wild-type and
IL-13 transgenic mice at 10 wk
of age after formalin fixation,
paraffin embedding, and staining
with hematoxylin and eosin.
Low power magnification (origi-
nal magnification 310) demon-
strates that compared with their
wild-type littermates (A), signifi-
cant areas of transgenic thymus
lack thymocyte populations (B).
Higher power magnification
(original magnification 320) in-
dicates that whereas wild-type
thymus contains distinct cortical
and medulla structure (C), this is
lost in transgenic thymus (D).
Figure 3. Thymocyte number
and surface phenotype. (A) Sin-
gle cell suspensions prepared
from thymus and LN were ana-
lyzed for surface expression of
CD4 and CD8. (B) Thymus
samples were also analyzed for
surface expression of CD44 and
CD25. In this case, CD42CD82
CD32 thymocytes were analyzed
for expression of CD44 and
CD25.403 Emson et al. Brief Definitive Report
thymocyte populations may appear similar in these disparate
models, it seems likely that they arise by different mechanisms,
and that the CD41CD81 thymocyte subset is uniquely sen-
sitive to modulatory stimuli for reasons that have yet to be
elucidated. It is noteworthy that IL-4 transgenic mice also de-
velop an arrest in the normal development of CD41CD81
thymocytes in the thymus, with a coincident breakdown in
the typical structure of thymic medulla and cortex (18, 19,
21). However, despite the reduction in numbers of CD41
CD81 thymocytes in IL-4 transgenic mice, these animals, un-
like the IL-13 transgenics described here, are not reported
to have large areas of the thymus devoid of thymocytes. Fur-
thermore, in contrast to the IL-13 transgenics, IL-4 transgenic
animals are reported to have losses in peripheral CD41 T
cells (19) or peripheral CD81 T cells (18, 21) depending on
the promoter used to control transgene expression.
Our data demonstrate that expression of IL-13 in vivo
can modulate IgE production even in the absence of IL-4,
and that the apparent discrepancies between the roles of
IL-13 in the murine and human systems appear to be due
to features inherent in the in vitro assay systems used for
their analysis. Thus, IL-13 transgenic animals represent an
important tool for defining the in vivo regulation of IgE by
IL-4 and IL-13 in disease.
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